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Abstract
Background: Carpal tunnel syndrome (CTS) is a common disorder, often treated with surgery
or wrist splinting. The objective of this economic evaluation alongside a randomized trial was to
evaluate the cost-effectiveness of splinting and surgery for patients with CTS.
Methods: Patients at 13 neurological outpatient clinics with clinically and electrophysiologically
confirmed idiopathic CTS were randomly allocated to splinting (n = 89) or surgery (n = 87). Clinical
outcome measures included number of nights waking up due to symptoms, general improvement,
severity of the main complaint, paraesthesia at night and during the day, and utility. The economic
evaluation was performed from a societal perspective and involved all relevant costs.
Results: There were no differences in costs. The mean total costs per patient were in the surgery
group EURO 2,126 compared to EURO 2,111 in the splint group. After 12 months, the success
rate in the surgery group (92%) was significantly higher than in the splint group (72%). The
acceptability curve showed that at a relatively low ceiling ratio of EURO 2,500 per patient there is
a 90% probability that surgery is cost-effective.
Conclusion: In the Netherlands, surgery is more cost-effective compared with splinting, and
recommended as the preferred method of treatment for patients with CTS.
Background
Carpal tunnel syndrome (CTS), caused by compression of
the median nerve at the wrist. In the Netherlands, the
prevalence of electrophysiologically confirmed CTS in the
adult general population was found to be 0.6% in men
and 3.4% in women [1]. In Sweden, prevalence was 2.1%
and 3.0%, respectively [2]. Patients with CTS are often
treated with surgery or conservative methods of treatment
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(e.g. wrist splinting). A systematic review showed that
open carpal tunnel release was the most suitable surgical
technique [3]. One Cochrane review found that a hand
brace and carpal bone mobilisation significantly
improved symptoms and ultrasound treatment, oral ster-
oid treatment and yoga significantly reduced pain [4].
Another Cochrane review demonstrated clinical improve-
ment of symptoms of carpal tunnel syndrome at one
month following local corticosteroid [5]. Two recent sys-
tematic reviews confirmed these findings [6,7]. There is
still no consensus on whether surgery or conservative
treatment is the best approach for patients with CTS [8-
10].
Only two articles reported on the cost-effectiveness of sur-
gical treatment options for CTS. Both studies compared
endoscopic carpal tunnel release with open carpal tunnel
release, and were based on decision-analytic simulation
models [8,9]. One study concluded that endoscopic car-
pal tunnel release seemed to be a cost-effective procedure
[8]. The other study concluded that the two techniques
had similar total costs [9]. No cost-effectiveness analysis
has yet been published in which surgery is compared with
a conservative treatment option.
Therefore, we performed an economic evaluation along-
side a randomized-controlled trial (RCT), to evaluate the
cost-effectiveness and cost-utility of surgery compared
with splinting for patients with CTS. An evaluation of the
clinical outcomes of this trial has been reported elsewhere
[10].
Methods
The medical ethics committees of the 13 participating
hospitals approved the study protocol of this multicenter
RCT. A detailed description of the design and an evalua-
tion of the clinical outcomes of this trial have been
reported elsewhere [11,12].
Study population
From October 1998 to April 2000, patients were recruited
by neurologists in 13 participating hospitals. Patients
were included if they: (1) had clinical and electrophysio-
logically confirmed CTS, (2) were 18 years of age or older,
(3) and were able to complete written questionnaires (in
Dutch). Patients were excluded from the trial if they: (1)
were previously treated with splinting or surgery, (2) had
a history of wrist trauma or surgery, (3) had a history sug-
gesting underlying causes of CTS (e.g. diabetes mellitus,
pregnancy), (4) had clinical signs or symptoms, or elec-
trophysiological findings suggesting conditions that could
mimic CTS or interfere with its validation (e.g. cervical
radiculopathy, polyneuropathy), or (5) had severe thenar
muscle atrophy.
Treatment
After giving written informed consent and undergoing a
baseline assessment, patients were randomly allocated to
either splinting or surgery. Patients allocated to splinting
were referred to a plaster-cast technician, an occupational
therapist or a home-care store, depending on the usual
procedures of the hospital at issue. They received either a
prefabricated splint (trademark Tricodur, Beiersdorf) or a
custom-made splint (made of soft-cast), that immobilized
the wrist in neutral position. Patients were instructed to
wear the splint during the night for at least 6 weeks and
during the day only if they wished to. There were no
restrictions for the patients in their work or normal daily
activities. After 6 weeks the neurologist discussed with the
patient whether any further treatment was necessary (con-
tinued splinting, other conservative treatment options or
surgery).
For patients allocated to surgery, an appointment was
made with a general surgeon, neurosurgeon, plastic sur-
geon or orthopaedic surgeon for outpatient standard open
carpal tunnel release surgery (without epineurotomy or
internal neurolysis, depending on the usual procedures of
the hospital at issue). The patient was encouraged to use
the hand as much as possible, and no absolute period off
work was recommended.
Outcome assessment
At baseline and 3, 6 and 12 months after randomization
patients visited the hospital and completed written ques-
tionnaires. Clinical outcome measures included: (1) gen-
eral improvement scored by the patients on a 6-point
ordinal transition scale, ranging from 'completely recov-
ered' to 'much worse'. A priori, success was defined as
'completely recovered' or 'much improved', (2) number of
nights waking up due to the symptoms during the past
week, (3) severity of the main complaint, and paraesthe-
sia at night and during the day, scored by the patient on
an 11-point numerical rating scale, ranging from 0 'no
symptoms' to 10 'very severe symptoms', (4) quality of life
measured by means of the EuroQol, and expressed as util-
ity (0–1) [13].
Economic evaluation
The aim of the economic analysis was to determine and to
compare the total costs related to CTS for patients treated
with splinting and for patients treated with surgery.
Firstly, relevant categories of resource utilization were
identified. Secondly, the volume of each category was
measured, and these volumes were multiplied by the
resource costs.
A societal perspective was the basis for the economic eval-
uation. Direct health care costs, direct non-health care
costs and indirect costs due to CTS were used as economicBMC Musculoskeletal Disorders 2006, 7:86 http://www.biomedcentral.com/1471-2474/7/86
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indicators. Direct health care costs included the costs of
the treatments (i.e. number of visits to medical specialist,
operation, and wrist splint), additional visits to a health
care provider (general practitioner, allied health profes-
sional, medical specialist or other health care profes-
sional), prescribed medication and professional home
care. Direct non-health care costs included costs of over-
the-counter medication, paid and unpaid help, visits to an
alternative therapist, time spent visiting a health care pro-
vider and travel expenses. Indirect costs of loss of produc-
tion, due to CTS-related absence from work, or hours of
inactivity, were also included.
Data regarding the use of all health care resources were
assessed by means of four cost diaries per patient covering
together the entire follow-up period of 12 months [14].
These diaries were completed by the patients and returned
to the research assistant at the hospital, who checked the
cost-diaries with the patients.
The direct health care and direct non-health care costs
(Table 1) were estimated according to the recently pub-
lished Dutch guidelines for cost analysis in health care
research [15,16]. In cases where these guidelines did not
apply, the tariffs of the Dutch Central Organization for
Health Care Charges were used to estimate costs [17]. The
costs of medication were estimated on the basis of prices
stated by the Royal Dutch Society for Pharmacy [18]. The
time spent by a patient when visiting a practitioner and
unpaid help were also included in the cost calculations,
for which a shadow price of EURO 7.94 per hour was used
[15].
Indirect costs of loss of production due to CTS, for both
paid and unpaid labor, were calculated. In the main anal-
ysis for paid labor, these costs were calculated according
to the Human Capital Approach, based on a mean income
of the Dutch population according to age and gender of
employees. For unpaid labor (e.g. voluntary work or
household work), the indirect costs were estimated using
a shadow price of EURO 7.94 per hour [15].
Statistical analysis
The economic evaluation was carried out according to the
intention-to-treat principle, i.e. the patients remained in
the group they were randomly allocated to at baseline. As
the percentage of missing cost data was only 9%, missing
cost estimates were substituted by the mean of the meas-
ured estimates from the patient at issue in the previous
period. To compare costs between groups, bootstrap con-
fidence intervals were computed. The 95% confidence
intervals were obtained by bias-corrected and accelerated
(BCa) bootstrapping, choosing 2000 as the number of
replications [19].
A cost-effectiveness analysis was performed, in which the
primary clinical outcomes of the trial were expressed as
mean improvement within each treatment group between
baseline and 12 month's follow-up. A cost-utility analysis
was also performed, in which the effects were expressed as
utilities, based on the EuroQol. The cost-effectiveness and
cost-utility ratios were calculated by dividing the differ-
ence between the mean costs by the difference between
the mean improvement in the clinical outcomes. Cost-
effectiveness ratio and cost-utility ratio were calculated
with bootstrapping according to the bias-corrected per-
centile method [20]. The bootstrapped cost-effect pairs
were graphically represented on a cost-effectiveness plane.
Acceptability curves were calculated, which show the
probability that a treatment is cost-effective at a specific
ceiling ratio [21].
Sensitivity analysis
Patients experienced difficulties in specifying the precise
number hours of unpaid help. Because of this uncertainty,
the influence of this cost-category on the total costs was
evaluated. In the first sensitivity analysis neither the costs
for unpaid help nor the costs for absenteeism from
unpaid labor were included. In the second analysis, only
costs for unpaid help were included. In the third analysis,
the indirect costs for paid labor were calculated according
to the Friction Cost Approach [22]. The basic idea of the
FCA is that the amount of production loss (and/or the
costs of maintaining production) due to sick leave, will
depend on the time-span needed to restore the initial level
Table 1: Prices used in the economic evaluation
EURO
Direct health care costs
Outpatient appointment 40.85
Hospitalisation (per day) 235.95
Operation carpal tunnel syndrome 69.50
Splint 72.10
General practitioner (visit of max. 20 min.) 16.60
Manual therapist (visit of max. 45 min.) 25.90
Physical therapist (visit of max. 30 min.) 18.15
Cesar exercise therapist (per visit) 17.70
Professional home care (per hour) 22.70
Direct non-health care costs
Unpaid help (per hour) 7.94
Time spent visiting a health care provider (per hour) 7.94
Indirect costs
Absenteeism paid labour (per day) * -
Absenteeism unpaid labour (per hour) 7.94
Euro 1 = US $0.90; * Costs for paid labour were calculated on the 
basis of a mean income of the Dutch population according to age and 
sex.[14,15]BMC Musculoskeletal Disorders 2006, 7:86 http://www.biomedcentral.com/1471-2474/7/86
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of production and costs. Sick employees can be replaced
after a necessary period of adaptation, the so-called fric-
tion period, which was estimated to be 122 days in the
Netherlands [22].
Results
A total of 176 patients was included in the trial, and they
were randomized to splinting (n = 89) and surgery (n =
87). Overall, 83 (93%) in the splint group and 73 (84%)
in the surgery group completed the follow-up measure-
ment 12 months after randomization. The main reason
for withdrawal in the splint group was 'lack of time', and
in the surgery group the main reason was 'unwillingness
to undergo surgery' (Figure 1). Every patient had to fill in
four cost diaries, covering together the entire 12 months
follow-up period, resulting in a total of 704 cost diaries.
Only 61 cost diaries (9%) were not returned. In total from
79 patients in the surgery group and from 88 patients in
the splint group were cost data available.
Clinical effects
The success rates (based on the outcome measure general
improvement) and improvement in the other clinical out-
come measures at 12 months are presented in Table 2. The
success rate in the surgery group (92%) was significantly
higher than in the splint group (72%). Surgery was also
significantly superior to splinting with regard to severity
of the main complaint and paraesthesia during the day.
There were no statistically significant differences with
regard to number of nights waking up due to symptoms
and paraesthesia at night. The utility in the surgery group
after 12 months was 0.85 (SD: 0.12), compared to 0.81
(SD: 0.16) in the splint group, not statistically significant
difference.
Utilization of health care resources
The utilization of health care resources and work absen-
teeism during the follow-up period of 12 months is pre-
sented in Table 3. Visits to health care providers were
mainly restricted to medical specialist care. The patients in
the splint group visited medical specialists more often
than the patients in the surgery group, because a number
of patients underwent surgery after their initial treatment
with a wrist splint. Patients in both groups seldom visited
a general practitioner or an allied health professional.
Only one patient in the surgery group and two patients in
the splint group visited an alternative therapist. Twelve
patients in the splint group used medication on prescrip-
tion, compared to sixteen patients in the surgery group.
The number of patients using over-the-counter medica-
tion was higher in the surgery group (n = 35; 44%) than
in the splint group (n = 20; 22%). In the surgery group 73
of the 87 patients underwent surgery, while fourteen
patients refused to undergo the operation. All patients in
the splint group received a splint at the beginning of the
trial. After one year, 33 patients (39%) in the splint group
had also undergone surgery.
The number of hours that patients received unpaid help
was high in both groups. In the surgery group 42 patients
(53%) received unpaid help, compared to 26 patients
(30%) in the splint group.
At baseline, 50 patients (57%) in the surgery group had a
paid job, compared to 53 patients (60%) in the splint
group. During the trial, 34 patients in the surgery group
had been absent from paid labor (mean of 12.1 days).
One patient had a very long period of work absenteeism
of 248 days. Twenty patients in the splint group had been
absent from work (mean of 11.8 days). In the splint
group, four patients had long periods of work absentee-
ism, varying from 120 to 260 days. If those five patients
with long periods of work absenteeism were excluded
from the analysis, the mean number of days of absentee-
ism of those who had been absent from paid labor in the
surgery group decreased from 12.1 to 9.2 days and in the
splint group from 11.8 to 3.1 days.
The findings were similar for absenteeism from unpaid
labor: 46 patients in the surgery group, compared to 36
patients in the splint group could not perform their nor-
mal daily activities for approximately 50 hours during the
12 months of the trial.
Costs
Table 4 shows the mean costs per treatment group and the
differences in mean costs between the groups during the
follow-up period of 12 months. The mean direct health
care costs were statistically significantly lower for surgery.
The main contributor to the direct non-health care costs
was the cost of help from family and friends. The total
direct costs in the surgery group were lower, compared to
the splint group. The indirect costs in the surgery group
were EURO 1,544 compared to EURO 1,427 in the splint
group. The total costs were EURO 2,126 in the surgery
group and EURO 2,111 in the splint group.
Cost-effectiveness and cost-utility analyses
In Table 5 the cost effectiveness and cost utility ratios are
presented. The cost-effectiveness ratio for surgery com-
pared to splinting for 'number of nights waking up due to
symptoms' was EURO -40, meaning that surgery was
EURO 40 cheaper in achieving one time less waking up at
night than splinting. Figure 2 shows the cost-effectiveness
plane for this outcome measure. 56% of the incremental
cost/effect pairs are located in the north-east quadrant and
39% are located in the south-east quadrant. The other out-
come measures showed similar results. Surgery was statis-
tically significantly more effective than splinting. Because
the total costs of both interventions were similar, the cost-BMC Musculoskeletal Disorders 2006, 7:86 http://www.biomedcentral.com/1471-2474/7/86
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effectiveness ratios did not provide additional informa-
tion. In Figure 3 the acceptability curve for number of
nights waking up due to the symptoms is presented for
surgery compared to splinting. This curve shows that at a
relatively low ceiling ratio of EURO 2,500 per patient
there is a 90% probability that surgery is cost-effective.
Sensitivity analysis
In the sensitivity analyses the cost-categories included in
the direct non-health care costs and the indirect costs were
varied. Many patients reported unpaid help as well as
absenteeism from unpaid work. In the first sensitivity
analysis the costs of help from family and friends and the
Progress of patients through Carpal Tunnel Syndrome (CTS) trial Figure 1
Progress of patients through Carpal Tunnel Syndrome (CTS) trial. * Reasons for withdrawal from the study (n = 19): 
refused to undergo surgery (n = 8); private matters (n = 2); lack of time (n = 1); died of cancer (n = 1); unable to attend the 
hospital at 12 months (n = 2); did not return the final questionnaire (n = 5). ** Reasons for withdrawal from the study (n = 10): 
lack of time (n = 3); private matters (n = 1); not satisfied with treatment result (n = 1); unable to attend the hospital at 12 
months (n = 1); did not return the final questionnaire (n = 4).
  Examined for eligibility by the neurologists
 (n=326)
Not randomized
  Not eligible:
 No electrophysiologically
 confirmed CTS
 Language barriers
 Already treated with a splint
  Previous wrist trauma or
 surgery
 Underlying causes of CTS 
 Polyneuropathy
 Severe thenar muscle atrophy
  Unwilling to participate:
 Strong preference for
 splinting or surgery
Other reasons
(n=111)
(n=5)
(n=9)
(n=8)
(n=4)
(n=10)
(n=2)
(n=1)
(n=23)
(n=39)
(n=10)
(n=39)
(n=1)
(n=1)
(n=4)
(n=6)
(n=10)
(n=1)
(n=8)
(n=6)
(n=2)
 Examined for eligibility by the
 research physiotherapists
 (n=215)
 Randomized after informed consent
 (n=176)
Allocated to surgery (n=87)
Did not receive intervention according to protocol
(n=14)
Allocated to splinting (n=89)
Did not receive intervention according to protocol
(n=13)
Follow-up and analysis:
1 month (n=80)
3 months (n=78)
6 months (n=77)
12 months (n=73)
18 months (n=68)*
Follow-up and analysis:
1 month (n=88)
3 months (n=86)
6 months (n=84)
12 months (n=83)
18 months (n=79)**BMC Musculoskeletal Disorders 2006, 7:86 http://www.biomedcentral.com/1471-2474/7/86
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costs of absenteeism from unpaid labor were excluded,
and this obviously resulted in lower direct non-health
care, indirect and total costs. However, this did not influ-
ence the results. The other sensitivity analyses also
showed no substantial changes in the results (data not
shown). The sensitivity analysis using the Friction Cost
Approach, in which the maximum friction period of 122
days was used for the five patients with long periods of
work absenteeism, did not change the results.
Discussion
In this trial, the cost-effectiveness and cost-utility of two
commonly applied methods of treatment for CTS was
evaluated. The results of the intention-to-treat analyses
showed that after 3 and 6 months surgery was clearly
more effective than splinting on all outcome measures
[11]. After 12 months, the success rate in the surgery
group was 92% and in the splint group 72%.
The mean direct health care costs in the surgery group
were a little bit lower than in the splint group. This was
due to the fact that a substantial number of patients in the
splint group received surgery after their treatment with a
wrist splint. Furthermore, in the Netherlands the cost of
open carpal tunnel release surgery is even lower than the
cost of a wrist splint. These two facts contributed to lower
direct health care costs in the surgery group. Some patients
in the splint group received a custom-made splint, and
others a prefabricated splint. The cost of a visit to the per-
son who makes the custom-made splint or provides the
prefabricated splint was calculated to be the same as a visit
to a medical specialist. However, in the Netherlands
patients can also obtain a standard splint in a home-care
store where no extra charges are made.
In this trial, different types of surgeons operated on the
patients. In the Netherlands the standard tariff for an
intervention is increased with a percentage that varies
according to the specialism of the surgeon (i.e. general
surgeon 24.5%, neurosurgeon 43.5%). Only the standard
tariff for a general surgeon was used in this study, instead
of different tariffs for different types of surgeons. The
direct non-health care costs and the total direct costs were
lower in the surgery group than in the splint group, but
these differences were not statistically significant.
The mean total costs after 12 months were EURO 2,126
(SD 4,618) in the surgery group and EURO 2,111 (SD
5,568) in the splint group. Consequently, the outcome
measures are decisive which treatment option should be
given to patients with CTS. This randomized controlled
trial with an economic evaluation showed that, compared
to splinting, surgery had better clinical effects and there
were no difference in the costs. Therefore, on the basis of
Table 3: Utilisation of health care resources and work absenteeism per treatment group during 12 months follow-up
Type of utilisation [Unit of measurement] Surgery* (n = 79) Splint* (n = 88)
Medical specialist care [no. of outpatient visits]** 2.5 (1.4) 3.3 (1.8)
General practice [no. of visits] 0.7 (1.5) 0.3 (0.7)
Allied health professions [no. of treatment sessions]*** 0.7 (4.6) 0.8 (3.4)
Professional home care [no. of hours] 0.3 (2.3) 0.5 (3.3)
Unpaid help [no. of hours] 40 (151) 39 (110)
Absenteeism paid labour [no. of days] 12.1 (31) 11.8 (42.8)
Absenteeism unpaid labour [no. of hours] 50 (141) 52 (143)
*Presented are the mean (standard deviation); ** Including the number of visits for the randomly allocated intervention; *** Allied health 
professions are physiotherapy, manual therapy, exercise therapy.
Table 2: Primary outcome measures for the treatment groups after 12 months
Primary outcome measures Surgery (n = 73) Splint (n = 83) Difference*
Success rate (%)** 92% (67/73) 72% (60/83) 20% (8; 31)
# nights waking up due to complaints (0–7)** 3.6 (2.9) 2.9 (3.0) 0.7 (-0.2; 1.7)
Severity of the main complaint (0–10)** 6.4 (2.7) 5.1 (3.1) 1.3 (0.4; 2.2)
Paraesthesia during the day (0–10)** 5.5 (2.9) 4.0 (3.4) 1.5 (0.5; 2.5)
Paraesthesia at night (0–10)** 5.2 (3.6) 4.5 (3.4) 0.7 (-0.4; 1.8)
Utility (EuroQol; 0–1)*** 0.85 (0.12) 0.81 (0.16) 0.04 (-0.004; 0.08)
*Presented are the difference in success rate and the differences in the mean improvements from baseline (95% confidence interval); **Presented 
are the success rate and the mean (standard deviation) improvements from baseline; ***Utility is scored for one year.BMC Musculoskeletal Disorders 2006, 7:86 http://www.biomedcentral.com/1471-2474/7/86
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the results of this study, surgery is clearly the superior
method of treatment for patients with CTS. This is not in
line with the recommendation of The American Academy
of Neurology that advises treatment of CTS with non-
invasive options (e.g. splinting) initially, and OCTR only
if non-invasive treatment proves to be ineffective [23].
A limitation of this study is that the results may be limited
in how they can be applied to other countries in which the
costs of surgery would be much higher. As surgery is much
more expensive in other countries than in the Nether-
lands, results of this study may not be directly extrapo-
lated. It is important to realize that the costs used in an
economic evaluation are the real costs of the intervention
and not the price that is paid by either the (public or pri-
vate) health insurers and/or the patients. Not the prices
charged for this intervention, but the real cost price
should be included as the costs of the intervention in the
economic evaluation. The real cost price is based on per-
sonnel, material and overhead costs. This intervention is a
simple outpatient intervention, the surgeon and nurse
don't spend more than 10–15 minutes to perform the
Cost-effectiveness plane comparing surgery and splinting for number of nights awake due to symptoms Figure 2
Cost-effectiveness plane comparing surgery and splinting for number of nights awake due to symptoms.
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more expensive
Less effective/
more expensive
Less effective/
less expensive
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Table 4: Mean total costs (in EURO) during 12 months follow-up (main analysis)*
Costs Surgery (n = 79) Splint (n = 88) Difference **
Direct health care costs 216 (161) 273 (163) -57 (-103;-10)
Direct non-health care costs 366 (1,213) 412 (1,124) -46 (-379;325)
Total direct costs 582 (1,256) 684 (1,198) -103 (-472;316)
Indirect costs 1,544 (3,508) 1,427 (4,514) 118 (-1,034;1,448)
Total costs 2,126 (4,618) 2,111 (5,568) 15 (-1,458;1,913)
EURO 1 = US $0.90; * Presented are the mean (standard deviation) costs; ** Presented are the differences in mean costs between the treatment 
groups (95% confidence interval obtained by bias corrected and accelerated bootstrapping).BMC Musculoskeletal Disorders 2006, 7:86 http://www.biomedcentral.com/1471-2474/7/86
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intervention, and material costs are low. Assuming a sal-
ary of Euro 200 per hour for the surgeon and 50 for the
nurse, the total personnel costs would be Euro 250/4
(assuming 15 minutes per intervention), which equals
Euro 62.50. So, the tariff of Euro 69.50 we used seems a
good proxy for the real cost price. The prices charged for
this intervention in other countries are much higher than
the actual cost price, which indicates that profits are (very)
high. Economic evaluations in other health care systems
(countries) are recommended, and these economic evalu-
ations should also use the real cost price and not charges.
Conclusion
In the Netherlands, surgery is more cost-effective com-
pared with splinting, and recommended as the preferred
method of treatment for patients with CTS.
Table 5: Cost effectiveness and cost utility ratios (in EURO) (main analysis)*
Costs Surgery (n = 73)** Splint (n = 82)** Ratio
Costs Effects Costs Effects
# Nights waking up due to complaints (0–7) 2,215 3.6 2,244 2.9 -40
Severity of the main complaint (0–10) 2,215 6.4 2,244 5.1 -21
Paraesthesia during the day (0–10) 2,215 5.5 2,244 4.0 -19
Paraesthesia at night (0–10) 2,215 5.2 2,244 4.5 -40
Utility (EuroQol; 0–1)*** 2,126 0.85 2,111 0.81 353
EURO 1 = US $0.90; *Presented are the mean (standard deviation) improvements from baseline; ** Patients with missing data on either outcome 
measures or costs are excluded; *** Number of patients for utility in surgery (n = 79) and splint (n = 88).
Acceptability curve for surgery vs. splinting for number of nights awake due to symptoms Figure 3
Acceptability curve for surgery vs. splinting for number of nights awake due to symptoms. At a ceiling ratio of 
EURO 2500 per patient there is a 90% probability that surgery is cost-effective.
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